DIGIFAB 40mg powder infusion solution medication leaflet

V03AB24 antidigoxin antibodies • Various | All other therapeutic products | Antidotes

Antidigoxin antibodies are used as an antidote for the treatment of digoxin toxicity, a condition that can occur following excessive administration of digoxin, a medication used for heart failure and arrhythmias. These antibodies specifically bind to digoxin molecules in the blood, forming complexes that are then eliminated by the kidneys, thereby reducing the toxic effects of digoxin.

Antidigoxin antibodies are administered intravenously, usually in emergency situations, with the dosage calculated based on the serum digoxin level and the patient's weight.

Common side effects include injection site reactions, nausea, fever, and hypokalemia. In rare cases, severe allergic reactions or renal failure may occur.

Patients receiving antidigoxin antibodies should be closely monitored for signs of adverse reactions and serum digoxin levels. This treatment is essential for managing severe digoxin toxicity, providing a rapid and effective solution to reduce the risk of serious complications.

General data about DIGIFAB 40mg

Substance: antidigoxin antibodies

Date of last drug list: 01-07-2023

Commercial code: W69597001

Concentration: 40mg

Pharmaceutical form: powder infusion solution

Quantity: 1

Product type: generic

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: SERB - FRANTA

Holder: CN UNIFARM S.A. - ROMANIA

Number: 801/2023/01